Aline Herlopian
Neurology · New Haven, CTNPI 1790063899
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,173 of the $14,072 with a category attached, or 65.2%. 7 manufacturers reported payments, led by UCB, Inc. at 47.3% of the total. Reporting peaked in 2024 at $7,612 and has fallen 51.0% since, to $3,726 in 2025.
Across 29 payments — averaging $485.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$7K
- Jazz Pharmaceuticals Inc.$4K
- Medtronic$2K
- Natus Medical Incorporated$1K
- SK Life Science, Inc.$169
- Neuropace, Inc.$151
- plus $57 from 1 others
Across 40 payments — averaging $6458.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$148K
- SK Life Science, Inc.$92K
- AbbVie$18K
What the payments were for
- Consulting fees$9,17365%
- Speaking & faculty fees$1,0007%
- Travel & lodging$2,61419%
- Food & beverage$1,2859%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 8 | $6,657 |
| Jazz Pharmaceuticals Inc. | 10 | $3,646 |
| Medtronic | 5 | $2,392 |
| Natus Medical Incorporated | 1 | $1,000 |
| SK Life Science, Inc. | 3 | $169 |
| Neuropace, Inc. | 1 | $151 |
| Acadia Pharmaceuticals Inc | 1 | $57 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$6,522
- Epidiolex$3,405
- PERCEPT PC BRAINSENSE$2,160
- RNS Neurostimulator Kit$151
- ACTIVA PC$101
How this compares
$14,072 in reported general payments places this provider in the 75th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FinteplaFenfluramine Hcl | 50 | $854,400 |
| BriviactBrivaracetam | 394 | $671,611 |
| EpidiolexCannabidiol (Cbd) | 125 | $541,954 |
| XcopriCenobamate | 235 | $355,156 |
| OnfiClobazam | 24 | $91,656 |
| XifaxanRifaximin | 25 | $84,679 |
| VimpatLacosamide | 65 | $80,415 |
| Oxtellar XrOxcarbazepine | 66 | $73,676 |
| Clobazam | 552 | $70,755 |
| AptiomEslicarbazepine Acetate | 26 | $65,873 |
| LamictalLamotrigine | 20 | $58,588 |
| Lamotrigine ErLamotrigine | 187 | $54,963 |
| Rufinamide | 48 | $52,757 |
| FycompaPerampanel | 28 | $42,511 |
| KeppraLevetiracetam | 28 | $41,169 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Fintepla, Briviact, Vimpat, Nayzilam | $6,657 | $1,622,592533 claims |
| SK Life Science, Inc.Xcopri | $169 | $355,156235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 280 neurology providers in Connecticut.
Other neurology in New Haven
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Stephen WaxmanNew Haven$252K
- Ariel LeflandNew Haven$220K
- David RussellNew Haven$208K
- Richard NowakNew Haven$126K
- David HaflerNew Haven$118K
- Kenneth MarekNew Haven$86K
- Daniel DicapuaNew Haven$85K
- Lee SchwammNew Haven$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.